Centessa Pharmaceuticals plc — Director's Dealing 2025

Nov 18, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Centessa Pharmaceuticals plc (CNTA)
CIK: 0001847903
Period of Report: 2025-11-17

Reporting Person: HUSSAIN IQBAL J (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-17	Ordinary Shares	M	6000	$5.84	Acquired	111386	Direct
2025-11-17	Ordinary Shares	S	6000	$27.6392	Disposed	105386	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-11-17	Share Option (right to buy)	$5.84	M	6000	Disposed	2031-02-19	Ordinary Shares (6000)	Direct

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2024.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.505 to $27.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.